Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis - Summary - MDSpire
Advertisement
Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis
To compare the effects of planned, time-limited withdrawal versus continuous maintenance of IL inhibitors specifically in psoriasis patients who have achieved clinical remission.
Key Findings:
Planned withdrawal of anti-IL therapy is associated with inferior remission maintenance compared to ongoing therapy, which may have significant implications for treatment strategies.
No reduction in adverse event rates was observed with withdrawal.
Bimekizumab and guselkumab showed superior outcomes for PASI 90 endpoints compared to other anti-IL therapies.
Interpretation:
The findings suggest that while withdrawal may be necessary for certain clinical situations, it generally leads to worse outcomes in terms of maintaining remission in psoriasis patients, indicating a need for careful risk assessment.
Limitations:
The study did not include observational studies, which may provide additional insights into long-term outcomes.
The analysis is limited to the data available from the selected clinical trials.
Conclusion:
Scheduled temporary withdrawal of anti-IL biologics in psoriasis patients may not be advisable due to the risk of relapse and lack of adverse event reduction, highlighting the need for ongoing maintenance therapy.
